Pulmonx

Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It carries out its operations in the following geographical locations: Europe, Middle East and Africa (EMEA), Asia Pacific, Other International and United States. The firm offers the Zephyr Endobronchial Valve, an implantable device used to occlude all airways feeding the hyperinflated lobe of a lung that is most diseased with emphysema. It also offers StratX Lung Analysis, a platform designed to treat severe emphysema and the Chartis Assessment System, a pulmonary assessment system. The company was founded by Rodney C. Perkins in December 1995 and is headquartered in Redwood City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pulmonx reports robust sales growth and eyes Japan expansion

Pulmonx shows strong sales growth and margin improvement in 2022
Balancing expenses and growth focus while navigating regulatory challenges
Confidence in future revenue growth through market expansion and account productivity

Pulmonx reports stellar Q1 sales growth and strategic initiatives

Pulmonx's Q1 2023 performance reflects robust sales growth, strategic commercial initiatives, and a focus on customer engagement. While challenges in profitability persist, the company's strong financial position and confidence in its strategy bode well for future growth and operational efficiency.

Pulmonx reports record sales in Q2 2023, eyes international expansion

Pulmonx delivered strong sales growth in Q2 2023, with a focus on strategic expansion and market development.
While facing financial challenges and losses, the company's emphasis on operational efficiency and international expansion presents growth opportunities.
With an updated revenue guidance and solid gross margin, Pulmonx is poised for continued growth and market penetration in the respiratory device sector.

Pulmonx achieves record revenue, eyes international expansion and patient outcomes

Pulmonx reported strong revenue growth in Q3 2023, driven by U.S. sales and a focus on commercial strategy, with increased account productivity and new center openings.
While facing challenges in international sales and regulatory differences in Europe, the company remains optimistic about future growth and the potential of the AeriSeal program.
Opportunities lie in international expansion, positive patient outcomes expected from the CONVERT 2 study, and investments in the right people and referral centers for enhanced patient care.

Pulmonx reports record sales in Q4 2023, eyes revenue growth

Pulmonx's strong financial performance in Q4 2023 and full year 2023 reflects growth and potential.
The company's strategic focus on product development and market expansion presents opportunities for future revenue.
Challenges include increased R&D expenses and market penetration efforts.
Overall, Pulmonx's performance and future plans indicate a positive outlook for growth and innovation.

Pulmonx reports robust Q1 earnings, eyes global expansion for growth

Pulmonx's strong Q1 performance, focus on innovation, and strategic growth initiatives position the company for long-term success.
While facing challenges in achieving profitability and managing expenses, Pulmonx's market opportunities and financial discipline are key strengths.
The company's outlook for 2024 remains positive, supported by revenue guidance, operational efficiency, and a commitment to patient care.
Investors should monitor Pulmonx's progress in key trials, international expansion, and financial metrics to assess its growth trajectory.

Pulmonx achieves record sales, focuses on growth and efficiency

Pulmonx reported strong sales growth and operational improvements in Q2 2024, despite a net loss.
The company's focus on expanding patient access and driving workflow efficiencies positions it well for future growth.
While facing financial challenges, Pulmonx has opportunities to enhance profitability through cost management and market expansion.
Overall, Pulmonx's strategic initiatives and performance indicate a positive outlook for the company's future.

Pulmonx posts strong Q3 earnings, eyes global expansion opportunities

Pulmonx delivered strong financial performance in Q3 2024, driven by robust U.S. revenue and international growth, positioning the company for future success.
With a focus on innovation, market expansion, and financial discipline, Pulmonx is well-positioned to capitalize on growth opportunities and navigate challenges effectively.
The company's solid cash position, successful clinical trials, and strategic initiatives underscore its potential for sustained growth and market leadership.
Pulmonx's commitment to training, automation, and awareness building, coupled with global expansion plans, bodes well for long-term value creation and competitive advantage.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. It operates through the United States, Europe, Middle East, Africa, Asia Pacific, and Other International segments. The company was founded by Rodney Perkins on December 26, 1995 and is headquartered in Redwood City, CA.

REDWOOD CITY, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the first quarter ended March 31, 2022.

Pulmonx Reports First Quarter 2022 Financial Results

REDWOOD CITY, Calif., April 26, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming Bank of America Securities 2022 Healthcare Conference in Las Vegas. Management is scheduled to present on Tuesday, May 10, 2022, at 12:40 PM PT / 3:40 PM ET.

Pulmonx to Present at the Bank of America Securities 2022 Healthcare Conference

REDWOOD CITY, Calif., April 19, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Tuesday, May 3, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report First Quarter 2022 Financial Results on May 3, 2022

Pulmonx Corporation (LUNG) CEO Glen French on Q4 2021 Results - Earnings Call Transcript

Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates

REDWOOD CITY, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2021 ended December 31, 2021.

Pulmonx Reports Fourth Quarter and Full Year 2021 Financial Results

REDWOOD CITY, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2022 Virtual Healthcare Conference on Thursday, February 24, 2022, at 8:45AM PT / 11:45AM ET.

Pulmonx to Present at the Citi 2022 Virtual Healthcare Conference

REDWOOD CITY, Calif., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2021 after the close of trading on Wednesday, February 23, 2022. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

The mean of analysts' price targets for Pulmonx Corporation (LUNG) points to a 53% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 53% Upside in Pulmonx Corporation (LUNG): Can the Stock Really Move This High?

REDWOOD CITY, Calif., Dec. 29, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will present at the upcoming 40th Annual J.P. Morgan Healthcare Conference. Management is scheduled to present on Tuesday, January 11, 2022, at 7:30 a.m. Eastern Standard Time.

Pulmonx to Present at the 40th Annual J.P. Morgan Healthcare Conference

Media-shy investment firm Primecap Management revealed earlier this week it boosted its stake in Pulmonx Corp. ( LUNG , Financial), impacting the equity portfolio by 0.03%.

Primecap Pumps Up Pulmonx Position

REDWOOD CITY, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) --  Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will participate in the 33rd Annual Piper Sandler Healthcare Conference being held from November 29 to December 2, 2021. Members of the management team will be participating in investor meetings on Wednesday, December 1, 2021.

Pulmonx to Present at the 33rd Annual Piper Sandler Healthcare Conference

Pulmonx Corporation (LUNG) CEO Glen French on Q3 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the third quarter ended September 30, 2021.

Pulmonx Reports Third Quarter 2021 Financial Results

REDWOOD CITY, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2021 after the close of trading on Tuesday, November 2, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

Pulmonx to Report Third Quarter 2021 Financial Results on November 2, 2021

The consensus price target hints at a 42.8% upside potential for Pulmonx Corporation (LUNG). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Pulmonx Corporation (LUNG) Climb 43% to Reach the Level Wall Street Analysts Expect?

Derrick Sung, Chief Financial Officer at Pulmonx (NASDAQ:LUNG), made a large insider sell on September 21, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Tuesday showed that Sung sold 6,000 shares of Pulmonx at prices ranging from $37.33 to $37.96.

Chief Financial Officer Of Pulmonx Makes $224.56 Thousand Sale

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Pulmonx Announces BCBS of Michigan and Horizon BCBS of New Jersey Issue Coverage Policies Providing Coverage for Treatment with the Zephyr® Valve

Pulmonx Announces Two Additional Significant Blue Cross Blue Shield Plans Now Provide Coverage for Severe Emphysema/COPD Treatment

Axsome Therapeutics

Vertex Pharmaceuticals

Stocks of biotech companies fighting COVID-19 have been great investments over the last two years. What stocks might zoom higher when the pandemic is over?

3 Healthcare Stocks That Might Skyrocket When COVID Is Over

REDWOOD CITY, Calif.--(BUSINESS WIRE)---- $LUNG #COPD--Positive Coverage Policy Gives Additional 34 Million People Access to Treatment with the Zephyr® Valve, a Minimally Invasive Treatment Option

Pulmonx Announces Anthem Blue Cross Blue Shield Now Provides Coverage for Severe COPD/Emphysema Treatment

Pulmonx Corporation (LUNG) CEO Glen French on Q2 2021 Results - Earnings Call Transcript

REDWOOD CITY, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for severe lung disease, today reported financial results for the second quarter ended June 30, 2021.

Pulmonx Reports Second Quarter 2021 Financial Results

Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors Alissa Hsu Lynch and Tiffany Sullivan join the Pulmonx Board of Directors

Pulmonx Welcomes Two New Board Members, Adding Expertise in Health Technology, Consumer Marketing, and Integrated Healthcare Delivery Networks

REDWOOD CITY, Calif.--(BUSINESS WIRE)-- #COPD--Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, today announced the publication of long-term follow-up data of the IMPACT Study, a multi-center randomized clinical trial of the Zephyr® Valves. The IMPACT data show that Zephyr Valves deliver significant benefits to a group of severe COPD/emphysema patients that have very few treatment options because of widespread destruction of lung

Pulmonx Announces Long-Term Follow-Up Data Confirming Significant Benefits of Zephyr Valve for Patients with Severe COPD/Emphysema

REDWOOD CITY, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2021 after the close of trading on Tuesday, August 3, 2021. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

News for Pulmonx Stock (LUNG)